Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: A meta-analysis

Menopause

Volumn 16, Issue 5, 2009, Pages 984-991

  Castelo Branco, Camil ^a   Ciria Recasens, Manel ^b   Cancelo Hidalgo, María J ^a   Palacios, Santiago ^c   Haya Palazuelos, Javier ^d   Carbonell Abelló, Jordi ^b   Blanch Rubió, Josep ^b   Martínez Zapata, María J ^e   Manasanch, José ^f   Pérez Edo, Lluís ^b  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b Rheumatology Unit   (Mexico)

^c Palacios Institute of Women's Health   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Bone mineral density; Calcium carbonate; Meta analysis; Ossein hydroxyapatite complex; Osteoporosis prevention

Indexed keywords

CALCIUM CARBONATE; COLECALCIFEROL; ESTRADIOL; OSSOPAN; OSTEOGENON; OSTEOPOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED STUDY; EMBASE; HUMAN; MEDLINE; OSTEOLYSIS;

ADMINISTRATION, ORAL; BONE DENSITY; BONE DISEASES, METABOLIC; BONE RESORPTION; CALCIUM CARBONATE; DURAPATITE; EVIDENCE-BASED PRACTICE; HUMANS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 73349100670     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181a1824e     Document Type: Article

References (51)

1. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral, density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-1259. (Pubitemid 26147662)
2. Schott AM, Cormier C, Hans D, et al. How hip and whole body bone mineral density predict hip fracture in elderly women. The EPIDOS prospective study. Osteoporos Int 1998;8:247-254. (Pubitemid 28427074)
3. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk?. JBone Miner Res 2000;15:183-187.
4. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-1592. (Pubitemid 34615244)
5. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapy. Bone 2004;34:599-604. (Pubitemid 38393794)
6. Gumming R, Cumming S, Nevitt M. Calcium intake and fracture risk: results from the study of osteoporotic fractures. Am J Epidemiol 1997;145:927-935.
7. Shea B, Wells G, Cranney A, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002;23:552-559.
8. Grant AM, Avenell A, Campbell MK, et al. RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium or Vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005;365:1621-1628.
9. Zárate A, Hernández M, Moran C, Angeles L. El enfoque moderno de la osteoporosis. Rev Fac Med UNAM. 2003;46:49-51.
10. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 200.1 ;285:785-795.
11. Annefeld M, Caviezel R, Schacht E, Schicketanz KH. The influence of ossein-hydroxyapatite compound on the healing of a bone defect. Curr Med Res Opin 1986;10:241-250. (Pubitemid 16021301)
12. Schmidt KH, Wörner VM, Buck HJ. Examination of new bone growth on aluminium oxide implant contact surfaces after oral administration, of ossein-hydroxyapatite compound to rats. Curr Med Res Opin 1988;11: 107-115.
13. Chavassieux P, Pastoureau P, Boivin G, Delmas PD, Chapuy MC, Meunier PJ. Effects of ossein-hydroxyapatite compound on ewe bone remodeling: biochemical and histomorphometric study. Clin Rheumatol 1991;10:269-273.
14. Castelo-Branco C, Vicente JJ, Haya J. Menopausia y osteoporosis: utilidad del complejo de oseína-hidroxiapatita. In: Castelo-Branco C, Haya Palazuelos J, eds. Osteoporosis y Menopausia. Madrid, Spain: Editorial Médica Panamericana, 2004:357-364.
15. Castelo-Branco C, Pons F, Vicente JJ, Sanjuán. A, Vanrell JA. Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial. J Reprod Med 1999;44:601-605. (Pubitemid 29350456)
16. Castelo-Branco C, Martinez de Osaba MJ, Pons F, et al. Osseinhydroxyapatite compounds for preventing postmenopausal bone loss. Coadjuvant use with, hormone replacement therapy. J Reprod Med 1999;44:241-246. (Pubitemid 29168791)
17. Lorenc RS, Tlustochowicz W, Hoszowski H, Lukaszkiewicz J, Biason P. The importance of past history of calcium supplementation on therapeutic effect of ossein-hydroxyapatite compound in osteoporotic females (abstract). Paper presented at: the 4th International Symposium on Nutritional Aspects in Osteoporosis; May 17-20, 2001; Lausanne, Switzerland.
18. Rtlegsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporos Int 1995;5:30-34.
19. Epstein O, Kato Y, Dick R, Sherlock S. Vitamin D, hydroxyapatite and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliar cirrhosis. Am J Clin Nutr 1982;26: 426-430.
20. Ciria M, Perez-Edo L, Blanch J, et al. Ossein-hydroxyapatite versus calcium carbonate effects in bone metabolism in primary senile osteoporosis (abstract). Bone 2005;36:S402.
21. SIGN 50: A Guidelines Developers' Handbook. Edinburgh, 2004. Methodology checklist 2: Randomised controlled trials. Available at http://www.sign.ac.uk/ guidelines/fulltext/50/checklist2.html. Accessed February 1, 2007.
22. Jadad AR, Moore RA, Carroll. D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996;117:1-12. (Pubitemid 26120810)
23. RevMan Analyses [computer program]. Version 1.0 for Windows. In: Review Manager (RevMan) 4.2, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
25. Chevalley T, Rizzoli R, Nydegger V, et al. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos Int 1994;4: 245-252. (Pubitemid 24291432)
26. Fernández-Pareja A, Hernández-Blanco E, Pérez-Maceda JM, Riera Rubio VJ, Palazuelos JH, Dalmau JM, Prevention of osteoporosis. Fouryear follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound. Clin Drug Invest 2007;27:227-232.
27. Tovey FI, Hall ML, Ell PJ, Hobsley M. Postgastrectomy osteoporosis. Br J Surg 19913B78:1335-1337.
28. Khadzhiev A, Rachev E, Katsarova M, Cherveniashki. S. The results of a clinical trial of the preparation. Ossopan. Akush Ginekol (Sofiia) 1990; 29:85-87.
29. Pines A, Raafat H, Lynn AH, Whittington J. Clinical trial of microcrystalline hydroxyapatite compound ("Ossopan") in the prevention, of osteoporosis due to corticosteroid therapy. Curr Med Res Opin 1984;8: 734-742. (Pubitemid 14173283)
30. Stěpán. JJ, Pospíchal J, Presl J, Pacovský V. Prospective trial of osseinhydroxyapatite compound in surgically induced postmenopausal women. Bone 1989;10:179-185. (Pubitemid 19249344)
31. Stellon A, Davies A, Webb A, Williams R. Macrocrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. Postgrad Med J 1985;61:791-796. (Pubitemid 15235225)
32. Albertazzi P, Steel SA, Howarth EM, Purdie DW. Comparison of the effects of two different types of calcium supplementation, on markers of bone metabolism in a postmenopausal osteopenic population with low calcium intake: a double-blind placebo-controlled trial. Climacteric 2004;7:33-40. (Pubitemid 38367161)
33. Lugli R, Brunetti G, Salvioli G. Effect of ossein hydroxyapatite compound (Ossopan®) on back pain in the elderly. Results of a placebo-controlled trial. Clin Trials J 1990;27:141-148. (Pubitemid 20238158)
34. Hegg R, Halbe WH, Fernandes CE, Sakamoto LC, Pinotti JA. Comparative study of the bone effects of ossein-hydroxyapatite complex versus calcium carbonate in osteopenic postmenopausal women. Rev Bras Med 2003;60:622-625. (Pubitemid 37214345)
35. Ringe JD, Keller A, Risk of osteoporosis in long-term heparin therapy of thromboembolic diseases in pregnancy: attempted prevention with ossein-hydroxyapatite. Geburtsh Frauenheilkd 1992;52:426-429.
36. Pelayo I, Haya J, De la Cruz JJ, et al. Raloxifene plus osseinhydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial. Menopause 2008;15:1132-1138.
37. Mackerras D, Lumley T. First and second year effects in trials of calcium supplementation of the loss of bone density in postmenopausal women. Bone 1997;21:527-533. (Pubitemid 28029696)
38. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan. A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370:657-666. (Pubitemid 47285316)
39. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from, a comparative meta-analysis of randomised controlled trials. J Clin Endocrinol Metab 2007;92:1415-1423. (Pubitemid 46556419)
40. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2003.
41. Recker RR. Clinical review 41: current therapy for osteoporosis. J Clin Endocrinol Metab 1993;76:14-16. (Pubitemid 23027544)
42. NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA 1994;272: 1942-1948.
43. Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European, women: new clinical findings from. BONE. Curr Med Res Opin 2005;21:391-401. (Pubitemid 40490679)
44. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women, with, osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838-1846. (Pubitemid 43877933)
45. Eisman. JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from, the DIVA study. J Rheumatol 2008;35:488-497.
46. Grupo de trabajo de la SEIOMM. Osteoporosis posmenopáusica. Guía de práctica clínica. Reemo 2002;11:67-78.
47. Prince RL, Devine A, Dhaliwal SS, Dick IM. Effects of calcium, supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006;166:869-875.
48. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354: 669-683. (Pubitemid 43247138)
49. Durance RA, Parsons V, Atkins CJ, Hamilton EBD, Davies C. A trial of calcium supplements (Ossopan) and ashed bone. Clin Trials J 1973;10: 67-74
50. Higgins JPT, Green. S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.0 [updated February 2008]. The Atrium, Southern Gate, Chichester, West Sussex, England; John Wiley & Sons Ltd, 2008. The Cochrane Collaboration, 2008. Available at:http://www. cochrane-handbook.org.Accessed October 1, 2008
51. Reid IR, Mason B, Home A, et al. Randomized controlled trial of calcium in healthy older women. Am J Med 2006;119:777-785. (Pubitemid 44291631)